Clinical Trial

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-06-13; most recent amendment 2026-03-30.
Status change: Not Yet Recruiting → Recruiting 2025-06-25
Trial Details
NCT Number NCT07033026
Lead Sponsor NGM Biopharmaceuticals, Inc
Conditions Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia
Enrollment 136 participants
Start Date 2025-06-25
Primary Completion 2027-04 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-04-01